High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

Abstract Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended in international guidelines. In thes...

Cijeli opis

Bibliografski detalji

Glavni autori:	Hanne Madsen, Charlotte G. Mortz, Carsten Bindslev‐Jensen, Mette Reilev, Jesper Hallas, Daniel P. Henriksen
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2021-12-01
Serija:	Clinical and Translational Allergy
Teme:	Adhärence antihistaminika nicht sedierend chronische urtikaria omalizumab richtlinie
Online pristup:	https://doi.org/10.1002/clt2.12085
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!